drugset / Trial / NCT05659537
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate safety of dulaglutide in participants with type 2 diabetes mellitus in India.
Timeline
- Start
- 2022-12-29
- Primary completion
- 2024-01-16
- Completion
- 2024-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dulaglutide | Peptide | 0.75 mg | Subcutaneous |
| Subject | Dulaglutide | Peptide | 1.5 mg | Subcutaneous |